Kyowa Kirin announces commitment to developing Rocatinlimab, a potential life-changing asset with significant market prospects. Innovative approach targets OX40 receptor on pathogenic T-cells to provide long-term disease control for patients with moderate to severe atopic dermatitis. Regulatory submission planned for first half of 2026. Kyowa Kirin to take back global control of Rocatinlimab program from Amgen. Positive results from Phase 3 studies published in The Lancet with promising efficacy and safety profile. Rocatinlimab developed based on company’s expertise in immunology and antibody engineering, offering potential treatment for various clinical scenarios of atopic dermatitis and other conditions. Plans for regulatory submissions in the US and Japan followed by global markets. Kyowa Kirin menegaskan komitmen terhadap pengembangan Rocatinlimab untuk dermatitis atopik, menunjukkan potensi untuk memberikan kawalan penyakit jangka panjang kepada pesakit. Rocatinlimab diharapkan dapat menjadi aset berharga dengan prospek pasaran yang signifikan. Penyerahan kepada pihak berkuasa pengawalseliaan dijadwalkan pada paruh pertama tahun 2026.

Read more at GlobeNewswire.: Kyowa Kirin akan Mengambil Alih Semula Kawalan ke atas